The new strain Lactobacillus pentosus CECT 7504 is provided. The strain presents as key advantages: a high survival to the antimicrobial factors found in vaginal fluid, factors that are often increased in a subset of patients with candidiasis, and that could be very harmful to many probiotics； the capacity to inhibit Candida albicans and Candida glabrata, thus displaying a broader spectrum activity to help manage Candida infections such as vulvovaginal candidiasis； the capacity to survive against high concentrations of antimycotic agents typically used to manage Candida infections, thus allowing its co-administration； and an improved capacity to acidify vaginal fluid, thus displaying a high potential to help manage bacterial vaginosis. Therefore, the strain and products comprising it are useful in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.
